tbuckley/cabot-search huggingface dataset:
A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
Authors: Manish A. Shah, Eduardo Patricio Yanez Ruiz, Gyorgy Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A. Wainberg, Johanna C. Bendell, Dung Thai, Pankaj Bhargava, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2019)

4 Background: Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. A phase I/Ib study of mFOLFOX6 + ADX revealed encouraging antitumor activity in patients (pts) with gastric or gastroesophageal junction (GEJ) adenocarcinoma (median first-line, progression-free survival [PFS] of 9.9 months). Methods: This phase 3, randomized, double-blind, multicenter study investigated the efficacy and safety of mFOLFOX6 with/without ADX in pts with untreated HER2-negative gastric or GEJ adenocarcinoma. Randomization was 1:1 to mFOLFOX6 + ADX or mFOLFOX6 + placebo (PBO). Oxaliplatin was administered on Days 1 and 15 of each 28-day treatment cycle (total of 6 cycles), followed by leucovorin and 5-fluorouracil dosing on Days 1 and 15 of each 28-day treatment cycle until disease progression. ADX/PBO 800 mg was infused on Days 1 and 15 of each 28-day cycle until disease progression. The study had 85% power (one-sided significance of 0.025) to detect a hazard ratio of 0.7 for overall survival (OS) by intention-to-treat analysis using the log-rank test. Secondary endpoints were PFS, objective response rate (ORR, RECIST 1.1), and safety. Results: Between September 2015 and May 2017, 432 pts were randomized; 218 pts to ADX and 214 pts to PBO. Median (95% CI) OS was 12.5 (11.2, 14.0) vs 11.8 (10.3, 13.5) months in the ADX and PBO groups, respectively (HR 0.93 [0.74, 1.18], two-sided p=0.56). Median PFS was 7.5 vs 7.1 months in the ADX and PBO groups, respectively (HR 0.84 [0.672, 1.038], two-sided p=0.10). Median investigator assessed ORR was 50.5% vs 41.1% in the ADX and PBO groups, respectively (two-sided p=0.049). The most common treatment-emergent adverse events were nausea, diarrhea, neutropenia, and fatigue. There were no meaningful differences in the safety profile of the ADX vs PBO groups. Subgroup analysis is ongoing. Conclusion: Additionof ADX to mFOLFOX6 does not improve OS in pts with untreated HER2-negative gastric or GEJ adenocarcinoma. Clinical trial information: NCT02545504.
Abstracts From the 35th American College of Nuclear Physicians Annual Meeting February 4–8, 2009 Clearwater, FL
Journal: Clinical Nuclear Medicine (2009)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Online First Collections ACNM MeetingsCMECommunication in OrganizationCOVID-19Feedback and RewardsFrom the American College of Nuclear MedicineHighly Cited and Frequently Read ArticlesPlanning and Conducting Meetings EffectivelyQuality and Safety in Health CareRecruitment of New PhysiciansTips for Giving a Memorable PresentationTips for LeadersTips for Physicians in Getting the Right Job ACNM ArticlesACNM Website For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
The Archives of Surgery, New England Surgical Society, and JAMA
Authors: A. E. Baue
Journal: JAMA (1986)

The April issue of theArchives of Surgeryfeatures publication of the annual program of the New England Surgical Society (NESS). This initiates a formal relationship of the society and the journal that will bring the new and exciting developments in surgery from medical centers in the six New England states to our readers. Also, in April, the<i>Journal of the American Medical Association</i>is calling attention to theArchives of Surgery, one of the nine specialty journals in the American Medical Associations' (AMA) family of publications. This emphasizes the collegiality and strengths that emanate from these relationships and the continuing dedication of the AMA to education. The addition of the NESS to the organizations associated with theArchivesprovides representation from the breadth of the country, from New England to the West—the Western Surgical Association and Southern California. The March issue of theArchives of Surgeryincluded the best
ACTR-25. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
Authors: Tomokazu Aoki, Yoshiki Arakawa, Tetsuya Ueba, Masashi Oda, Namiko Nishida, Yukinori Akiyama, Tetsuya Tsukahara, Nobuhiro Mikuni, Susumu Miyamoto
Journal: Neuro-Oncology (2017)

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m2/day) (Day 1–5) plus various doses of ACNU (30, 35, 40, 45 mg/m2/day) (Day 15) per 4 weeks was defined on a standard 3 + 3 design. In phase II, these therapeutic activity and safety of this regimen were evaluated. Forty-nine eligible patients were enrolled. The median age was 50 years-old. Eighty percent had a KPS of 70–100. Histologies were glioblastoma (73%), anaplastic astrocytoma (22%), anaplastic oligodendroglioma (4%). In phase I, 15 patients were treated at four cohorts by TMZ plus ACNU. MTD was TMZ (150 mg/m2) plus ACNU (40 mg/m2). In phase II, 40 patients were treated at the dose of cohort 3 (MTD). Thirty-five percent of patients experienced grade 3 or 4 toxicities, mainly hematologic. The overall response rate was 11% (4/37). Sixty-eight percent (25/37) had stable disease. Twenty-two percent (8/37) showed progression. Progression-free survival (PFS) rates at 6 and 12 months were 24% (95% CI, 12–35%) and 8% (95% CI, 4–15%). Median PFS was 13 months (95% CI, 9.2–17.2 months). Overall survival (OS) at 6 and 12 were 78% (95% CI, 67–89%) and 49% (95% CI, 33–57%). Median OS was 11.8 months (95% CI, 8.2–14.5 months). This phase I/II study showed a moderate toxicity in hematology and may has a promising efficacy in OS, without inferiority in PFS
Capivasertib Active against <i>AKT1</i>-Mutated Cancers
Journal: Cancer Discovery (2018)

The experimental pan-AKT inhibitor capivasertib (AZD5363) helped stabilize or shrink tumor growth in most patients with metastatic AKT1-mutant tumors enrolled in the U.S.-wide NCI-MATCH trial, according to data presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Residual Urine Determination by Roentgenographic and Isotope Means
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viral Infections in Humans
Authors: William W. Busse
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Viral respiratory infections can increase asthma symptoms in many patients. Although the mechanisms of these effects are not fully established, there is evidence that respiratory viruses can promote some components of allergic inflammation. In this regard, there is evidence that rhinovirus respiratory infections can lead to the development of late allergic reactions to inhaled allergen. This change in response to inhaled allergen supports the possibility that some respiratory infection will promote bronchial inflammation and may be a factor for increased wheezing with respiratory infection.
Reply:
Authors: Minoru Nakamura
Journal: Hepatology (2007)

We are pleased that Bogdanos and colleagues have undertaken an analysis of gp210 and centromere autoantibodies in their combined cohort of 332 patients with primary biliary cirrhosis (PBC) from Spain and Greece. The authors stated they used the same commercial anti-gp210 and anti-centromere enzyme-linked immunosorbent assay (ELISA) kits used by us. This is incorrect. We used the same commercial anti-centromere ELISA kits (INOVA Diagnostics Inc.), but we used an in-house anti-gp210 kit as described in Nakamura et al.2. We found, however, that the sensitivity and specificity of these 2 anti-gp210 kits are very similar (unpublished data). Therefore, we do not believe that the magnitude of the difference in seropositivity for anti-gp210 between the Japanese and Mediterranean cohorts is a result of the differences between the ELISAs employed in each study. We realize that in a short communication, Bogdanos et al. may not be able to present in detail the design of their clinical study nor the demographic features of patients with PBC, including sex, age, follow-up period, histological stage at the time of initial diagnosis, and the histological and/or clinical stage at the end of observation. This may reduce the quality of their cohort study. Furthermore, the majority of data were presented by way of a case-control study. The predictive values (odds ratio and/or hazard ratio) of anti-gp210 or anti-centromere were not presented. This may markedly reduce the strength of their conclusions. The seropositivity for anti-gp210 and anti-centromere antibodies in their study is much lower compared to our study in Japan. There are several possible explanations of this observation: (1) patients with PBC in their study involved more numbers of early-stage patients than our study, (2) the presence of ethnic/geographical variations or the different etiology between Mediterranean and Japanese populations, and (3) differences in the precise diagnostic criteria of PBC. We agree with Bogdanos et al. that further studies on large PBC cohorts from different ethnic and geographic regions are needed to clarify the universality of our observations using the same ELISA kits and look forward to the results of these studies. Minoru Nakamura M.D., Ph.D.*, * Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center and Department of Hepatology, Nagasaki University Graduate School of Medical Sciences, Omura, Nagasaki, Japan.
Health at home means watching the global village
Authors: J. Stephenson
Journal: JAMA (1995)

THE SLOGAN of the environmental movement, "Think globally, act locally," could be appropriated by physicians and others concerned about immigrants who carry infections endemic in their native lands as part of their personal baggage. Given the unprecedented reach of microbes through immigration and other factors such as travel and importation of foreign goods, physicians are discovering that they sometimes need to consider relatively exotic possibilities when diagnosing their patients' illnesses. Recent eruptions of deadly infections, such as Zaire's Ebola virus outbreak in May and last September's pneumonic plague epidemic in India, underscore the globalization of infections in a world shrunk by air travel. And while the real and potential risks posed by the influx of immigrants from areas where infections like tuberculosis (TB) and Chagas disease are endemic seem less cataclysmic than the possibility of a "hot zone" epidemic sweeping the planet, the former pose risks substantial enough to prompt
THE TRAINING OF INDUSTRIAL PHYSICIANS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neurological and neurosurgical conditions associated with aviation safety
Authors: W. R. Barclay
Journal: JAMA (1979)

This month the<i>Archives of Neurology</i>is publishing a special issue that deals with the current state of knowledge about selected neurological conditions. This authoritative document was solicited by the Federal Aviation Administration (FAA) to serve as a guide for physicians who examine airman applicants and make decisions concerning medical certifications. The document consists of panel statements on eight categories of major and commonly occurring neurological diseases: (1) cerebrovascular disease, (2) intracranial tumors, (3) head injuries, (4) demyelinating and degenerative diseases, (5) neuromuscular disorders and injuries to the peripheral and cranial nerves and spinal cord, (6) seizure disorders and disturbances of consciousness, (7) migraine and other headaches, and (8) dizziness and disorders of equilibrium. Each panel statement was developed by a group of nationally recognized experts who met in a two-day conference with invited guests and American Medical Association staff to arrive at a consensus. The final document was transmitted
The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice
Authors: Junko Wakabayashi, Zhongyan Zhang, Nobunao Wakabayashi, Yasushi Tamura, Masahiro Fukaya, Thomas W. Kensler, Miho Iijima, Hiromi Sesaki
Journal: The Journal of Experimental Medicine (2009)
American Surgeon, Baltimore
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ONCOPRE: A new chemotherapy benefit prediction algorithm to assist with treatment decision making.
Authors: Dimas Yusuf, Winson Y. Cheung, Maria Yi Ho
Journal: Journal of Clinical Oncology (2016)

e18090 Background: Electronic support tools can facilitate treatment decisions and inform care. Existing web-based tools such as Adjuvant! Online and Numeracy are frequently used by clinicians to estimate the benefits of adjuvant therapy to guide conversations with patients. However, existing applications neither consider more contemporary disease characteristics (e.g. microsatellite instability) nor operate on new handheld devices. Methods: A novel adjuvant chemotherapy benefit calculator for early stage colon cancer was designed to address the limitations of existing tools. It is based on historical outcomes, epidemiological data, and results of landmark trials that originally showed the benefits of various adjuvant chemotherapy regimens on outcomes. We compared estimates generated by our calculator with those derived by existing tools and validated the findings with real world population-based data from 7 centers in Canada. Results: An algorithm based on various patient factors, tumor characteristics, and prognostic biomarkers such as MSI was developed that predicted 5-year disease-free and overall survival (OS) in colon cancer. It provides unique predictions dependent on the selected disease stage and adjuvant treatment regimen. Results demonstrate that our outcome estimates compare favorably with findings from landmark clinical trials and population-based studies. Further, our estimates are more optimistic and precise when compared to historical data and estimates generated by existing calculators (see Table). Conclusions: ONCOPRE (www.oncopre.com/beta/) represents a new decision support tool that can assist in adjuvant therapy decision-making in colon cancer. Calculators must consider biomarkers as they improve capacity for prediction. Our platform serves as a potential model on which to develop prediction tools for other cancers. 5-year OS estimates. Patient ONCOPRE Mayo ACCENT Historical data Clinical trials 60M, stage 2 2a: 87% Not supported 2a: 85% 91% 2b: 83% 2b: 72% 2c: 57% 2c: 37% 75F, stage 3 3a: 79% 3a: 88.8% 3a*: 83% 80% 3b: 73% 3b: 67.0% 3b*: 64% (mean age 60) 3c: 59% 3c: 63.3% 3c*: 44% *mean age 60 40F, stage 2 2a*: 93% Not supported Not available 88% MSI +ve 2b*: 78% No chemo 2c: 57%
Phase II trial report of the new preoperative chemotherapy with S-1 and docetaxel for advanced breast cancer.
Authors: M. Nakagawa, M. Aoyama, M. Ikeda, M. Morimoto, H. Takechi, Y. Kawakami, K. Kennzaki, A. Tangoku
Journal: Journal of Clinical Oncology (2011)

1075 Background: Primary chemotherapy with anthracycline and taxanes is a gold standard regimen, which realizes pathological complete response (pCR) in 20% of patients with advanced breast cancer. However, sequential administration of anthracycline and taxanes includes serious side effects. This regimen is therefore difficult for use for high-risk patients. S-1 is a new oral anti-tumor drug. Combined treatment with docetaxel and S-1 yielded significant response in patients with gastric cancer with minimal side effects. We reported the interim clinical results of the efficacy and toxicity of S-1 combined with docetaxel in ASCO 2009 (abstract No.1121). This is a final report of the study including tumor gene expression assay. Methods: Patients with advanced breast cancer (stageII-IV) were treated with i.v. docetaxel (40mg/m2) on day1 and oral S-1 (80mg as FT/m2/day) on day1 to 14 every 3 weeks for 8 courses. The clinical response was evaluated every 3 months based on RECIST criteria. Primary endpoint is a pCR rate. Secondary endpoints are breast conservation rate, safety and predictors for response. Gene expression levels were measured with RNA from tumor specimens by TaqMan Array (Applied biosystems) for response related 190 genes. Results: Between March 2007 and May 2009, 46 women were enrolled. Premenopausal patients were 23.9%, Hormone receptor positive and HER2 positive patients were 76.0% and 34.7%, respectively. Among 40 assessable patients, 22.5% achieved pCR. Objective response rate was 77.5% and breast conservation rate was 90.0%. Adverse events over grade3 were peripheral sensory neuropathy, nausea and neutropenia. Five genes were picked up as the related genes between responder (CR) and others (PR, SD, and PD). Conclusions: The new regimen of S-1 combined with docetaxel is expected to exhibit satisfactory efficacy. Proper management is able to keep well S-1 compliances and improve response rate. Five genes as candidate of predictor for complete response were clarified.
Hospital use in a fee-for-service system
Authors: F. T. Nobrega
Journal: JAMA (1982)

The population of Olmsted County, Minnesota, receives care virtually exclusively from two fee-for-service group practices: the Mayo Clinic and the Olmsted Medical and Surgical Group. Study of the use of acute-care hospital services by this population in 1976 reveals that the hospital discharge rate per 1,000 population, adjusted for age and sex, was 30% less than the national rate; the age-sex-adjusted rate of hospital days per 1,000 population was 38% less than the national rate. Analysis by length of stay, type of hospital service, frequency of selected diagnoses and surgical procedures, and certain demographic and economic characteristics did not explain the differences from national use rates. These rates are comparable, after age and sex adjustment, with those in larger prepaid group practices. The analysis suggests that the organization of medical care may have an important influence on hospital use. (<i>JAMA</i>1982;247:806-810)
Clinical Toxicology
Authors: Joseph R. DiPalma
Journal: JAMA (1970)

A toxicology text is difficult to write because the subject is encyclopedic in nature and does not lend itself to codification. This one stresses what might be called domestic toxicology—those poisons which are encountered in the home, in the practice of medicine, and in the average coroner's office. Subjects of great societal importance today such as air pollutants and food additives are not discussed. A partial list of subject matter includes corrosive acids, caustics, cyanides, heavy metals, phosphorus compounds, toxic gases, halogenated hydrocarbons, petroleum products, and numerous plant alkaloids. As a British text it has a characteristic style of clean forthright exposition rare in American texts. The print is small but readable. It has the added feature of giving illustrative case reports at the end of each chapter. These are useful to the physician, the forensic expert, and to the legal profession. The book rates among the best which attempt